Incyte $INCY announced its updated results from the Phase 1 part of a Phase � clinical study, ECHO-202, evaluating the combination of epacadostat and Merck�s $MRK Keytruda (pembrolizumab) in treatment-naive advanced/metastatic melanoma patients. The outcome of the clinical trial is being presented at the European Society for Medical Oncology 2016 Congress in Copenhagen. The enrollment for the Phase 2 is underway.